RNAC — Cartesian Therapeutics Share News
0.000.00%
Last trade - 00:00- $186.98m
- $92.22m
- $2.80m
Cartesian Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cartesian Therapeutics Q2 net income steady
Brief: Cartesian Therapeutics Inc Q2 Net Income USD 15.769 Million
Cartesian Therapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
NASDAQ RESUMED AT 09:40 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:35 AM
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental
U.S. STOCKS ON THE MOVE-Nuvalent, Sirius XM, J.M. Smucker
Cartesian rises on China tie-up to develop new autoimmune cell therapy
Brief: Cartesian Therapeutics Announces Strategic Licensing Agreement With Westgene Biopharma To Accelerate The Development Of In Vivo Car-T Platform In Autoimmune Diseases
Brief: Cartesian Therapeutics Inc - Enters Loan And Security Agreement On May 22 - SEC Filing
Brief: Cartesian Therapeutics Inc - Phase 3 Aurora Topline Data In Myasthenia Gravis Expected In 1Q27 BLA Filing Planned Mid-2027
Cartesian Therapeutics Q1 net loss widens on higher R&D costs
Brief: Cartesian Therapeutics Inc Q1 Net Income USD -39.182 Million
Brief: Cartesian Therapeutics Highlights Recent Progress And Outlines 2026 Outlook
Brief: Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
Cartesian Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary